NASDAQ:HARP - Harpoon Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$14.63 -0.45 (-2.98 %)
(As of 02/20/2019 04:00 PM ET)
Previous Close$15.08
Today's Range$14.08 - $15.69
52-Week Range$13.25 - $15.97
Volume39,800 shs
Average Volume134,300 shs
Market Capitalization$349.79 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. It is involved in developing HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; and HPN536 for the treatment of ovarian cancer and other mesothelin expressing tumors, as well as other products targeting tumor-associated antigens for the treatment of multiple myeloma and small-cell lung cancer. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Receive HARP News and Ratings via Email

Sign-up to receive the latest news and ratings for HARP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HARP
CUSIPN/A
Phone650-443-7400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees45
Market Cap$349.79 million
OptionableNot Optionable

Harpoon Therapeutics (NASDAQ:HARP) Frequently Asked Questions

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Has Harpoon Therapeutics been receiving favorable news coverage?

Press coverage about HARP stock has been trending neutral this week, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Harpoon Therapeutics earned a news sentiment score of 0.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the near term.

Who are some of Harpoon Therapeutics' key competitors?

Who are Harpoon Therapeutics' key executives?

Harpoon Therapeutics' management team includes the folowing people:
  • Dr. Luke B. Evnin, Founder & Chairman (Age 56)
  • Dr. Gerald McMahon, Pres, CEO & Director (Age 64)
  • Dr. Holger Wesche Ph.D., Chief Scientific Officer (Age 50)
  • Dr. Natalie R. Sacks, Chief Medical Offer (Age 54)
  • Ms. Georgia L. Erbez, Chief Financial Officer (Age 52)

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

When does Harpoon Therapeutics' quiet period expire?

Harpoon Therapeutics' quiet period expires on Wednesday, March 20th. Harpoon Therapeutics had issued 5,400,000 shares in its IPO on February 8th. The total size of the offering was $75,600,000 based on an initial share price of $14.00. During Harpoon Therapeutics' quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Harpoon Therapeutics?

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $14.63.

How big of a company is Harpoon Therapeutics?

Harpoon Therapeutics has a market capitalization of $349.79 million. Harpoon Therapeutics employs 45 workers across the globe.

What is Harpoon Therapeutics' official website?

The official website for Harpoon Therapeutics is http://www.harpoontx.com.

How can I contact Harpoon Therapeutics?

Harpoon Therapeutics' mailing address is 4000 SHORELINE CT 250, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]


MarketBeat Community Rating for Harpoon Therapeutics (NASDAQ HARP)

Community Ranking:  1.4 out of 5 (star)
Outperform Votes:  2 (Vote Outperform)
Underperform Votes:  5 (Vote Underperform)
Total Votes:  7
MarketBeat's community ratings are surveys of what our community members think about Harpoon Therapeutics and other stocks. Vote "Outperform" if you believe HARP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HARP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by MarketBeat.com Staff

Featured Article: Index Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel